Kyowa Kirin (KYKOF) Stock Price, News & Analysis

Company Overview

Kyowa Kirin Co., Ltd. is a global biopharmaceutical company headquartered in Tokyo, Japan, specializing in the research, development and commercialization of innovative therapies. Established through the merger of Kyowa Hakko Kogyo Co., Ltd. and Kirin Pharma Co., Ltd. in 2008, the company operates as part of the Kirin Group and pursues a mission of delivering cutting-edge medicines in areas of high unmet medical need. Its corporate structure supports integrated research and development, manufacturing and worldwide licensing activities.

The company’s therapeutic focus spans oncology, nephrology, immunology and central nervous system disorders. Kyowa Kirin markets a range of antibody-based drugs and small-molecule therapies, including treatments for rare genetic and autoimmune conditions. Its pipeline features next-generation biologics, antibody-drug conjugates and cell therapies in various stages of clinical development. In addition to in-house projects, the company leverages strategic collaborations and licensing agreements to expand its product offerings and accelerate access to novel treatment modalities.

Kyowa Kirin distributes its products globally, with a strong presence in Japan, North America, Europe and Asia Pacific. It maintains research facilities and manufacturing sites in multiple regions to support clinical trials and commercial supply. The company’s management team, overseen by a President and CEO and supported by an experienced board of directors, is committed to advancing patient-centric innovation and fostering sustainable growth across its international footprint.

Key Stats

• Today's Range: $17.13 to $17.13
• 50-Day Range: $14.75 to $17.13
• 52-Week Range: $12.32 to $22.21
• Volume: N/A
• Average Volume: 1,204 shs
• Market Capitalization: N/A
• P/E Ratio: 0.50
• Dividend Yield: 116.40%
• Price Target: N/A
• Consensus Rating: N/A

Kyowa Kirin Stock Analysis - MarketRank™

Kyowa Kirin scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Kyowa Kirin.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyowa Kirin is 0.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyowa Kirin is 0.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.18.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kyowa Kirin has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Kyowa Kirin pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Kyowa Kirin does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Kyowa Kirin is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Kyowa Kirin has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kyowa Kirin has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Kyowa Kirin this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyowa Kirin insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 10.28% of the stock of Kyowa Kirin is held by institutions.

KYKOF Stock Analysis - Frequently Asked Questions

How have KYKOF shares performed this year?

Kyowa Kirin's stock was trading at $15.00 at the beginning of the year. Since then, KYKOF stock has increased by 14.2% and is now trading at $17.13.

How do I buy shares of Kyowa Kirin?

Shares of KYKOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/15/2025
• Next Earnings (Estimated): 10/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:KYKOF
• CIK: N/A
• Web: www.kyowakirin.com
• Phone: (135) 205-7200
• Fax: N/A
• Employees: 5,974
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A